JPRN-UMIN000006817已完成未知
iraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial in Japan - READ
Department of Cardiovascular Medicine, Saga University0 个研究点目标入组 20 人开始时间: 2011年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients will be excluded from the study when they meet to any of the criteria. (1)patients with cardiogenic shock (2)patient with serious liver disease((AST)GOT/(ALT)GPT>100) (3)patient with serious kidney trouble.(Cre>5mg/dl and patients under dialysis) (4)Patients with a past history of drug allergy and hypersensitivity. (5)Pregnant and/or breast-feeding at present,or a woman of child-bearing potential. (6)Patients with malignant neoplasms (7)Iinsulin-requiring diabetics.(Type 1,or type 2 with depletion of insulin secretion capacity.) (8)patients who was diagnosed that his/her condition is not appropriate to join this study.
研究者
相似试验
进行中（未招募）
不适用
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodMedDRA version: 8,0Level: PTClassification code 10012601Diabetes MellitusEUCTR2005-003417-32-BEovo Nordisk A/S1,865
进行中（未招募）
1 期
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodMedDRA version: 8,0 Level: PT Classification code 10012601Diabetes MellitusEUCTR2005-003417-32-GBovo Nordisk A/S100
进行中（未招募）
1 期
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodMedDRA version: 8,0Level: PTClassification code 10012601Diabetes MellitusEUCTR2005-003417-32-SKovo Nordisk A/S1,865
进行中（未招募）
不适用
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodDiabetes MellitusEUCTR2005-003417-32-IEovo Nordisk A/S1,865
进行中（未招募）
不适用
iraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension periodDiabetes MellitusEUCTR2005-003417-32-DKovo Nordisk A/S1,865